Drug manufacturing equipment with IPP’s global buyer network

Reliable drug manufacturing equipment is essential for pharmaceutical and biotech companies producing medicines, vaccines, and APIs. International Process Plants (IPP) offers one of the world’s largest inventories of surplus drug manufacturing equipment, with more than 15,000 assets in stock across 20 global sites. For nearly 50 years, IPP has helped companies secure affordable, proven equipment that meets industry standards and reduces time to market.

Why choose IPP for drug manufacturing equipment

IPP specializes in process industries, and our pharmaceutical inventory includes reactors, centrifuges, dryers, mixers, mills, and sterile processing systems. Unlike brokers or auction houses, IPP markets complete systems and individual assets that have been inspected and documented for quality and compliance.

For buyers, this means access to ready-to-ship drug manufacturing equipment that can be redeployed faster than new OEM orders, which often carry long lead times. For sellers, IPP’s international buyer network ensures surplus pharmaceutical equipment is marketed to companies actively seeking capacity worldwide.

Browse our process equipment overview to see pharmaceutical systems and equipment available today.

Search IPP’s IMS equipment marketplace to explore drug manufacturing equipment ready for immediate delivery.

Unlocking value with surplus pharmaceutical equipment

Drug manufacturing requires precision, consistency, and regulatory compliance. IPP helps companies expand or modernize production by sourcing equipment that is proven, reliable, and often already designed for FDA, EMA, or cGMP requirements.

Applications include:

• Active pharmaceutical ingredients (APIs): Reactors, filtration, drying, and crystallization equipment.
• Biologics and vaccines: Sterile fermentation, freeze dryers, and clean-in-place systems.
• Oral solid dosage: Mixers, granulators, fluid bed dryers, and tablet presses.
• Injectables and sterile manufacturing: Isolators, autoclaves, and aseptic filling systems.

Many of these assets become available because of plant consolidations, not because they are outdated. Redeploying them through IPP reduces capital costs while accelerating compliance-driven production.

The U.S. Food & Drug Administration (FDA) emphasizes equipment reliability and validation as central to cGMP compliance — making proven, surplus systems a practical alternative to new.

Key benefits of drug manufacturing equipment with IPP

• Immediate availability: Avoid long OEM lead times with equipment ready to ship.
• Lower capital costs: Acquire proven systems at significantly reduced prices.
• Regulatory compliance: Many assets designed for FDA, EMA, and cGMP standards.
• Global buyer access: Sellers connect with pharmaceutical and biotech firms worldwide.
• Turnkey support: IPP manages dismantling, logistics, and recommissioning.

With IPP, drug manufacturing equipment is not treated as surplus — it is repositioned as a valuable resource for companies scaling to meet global healthcare needs.

Learn more about IPP’s used equipment marketplace to explore pharmaceutical process systems available now.

PLUS:

>Princeton Junction-based IPP acquires fermentation plant in Minnesota

>Just Sold: Former Little Falls ethanol plant draws $2.5M

>IPP announces purchase of world-class Grimsby, UK API pharma manufacturing site from Novartis

Frequently asked questions about drug manufacturing equipment

Why buy used pharmaceutical equipment?

Used drug manufacturing equipment lowers capital costs, is immediately available, and often already meets regulatory standards.

Is surplus equipment reliable for pharmaceutical use?

Yes. Many systems are maintained to strict cGMP standards and can be validated for new production.

What types of equipment are in demand?

Reactors, centrifuges, dryers, mixers, tablet presses, and sterile systems are consistently sought after.

Does IPP handle relocation and validation support?

Yes. IPP manages dismantling, transport, and recommissioning to ensure smooth compliance transitions.

For more answers, visit our FAQs page.